Literature DB >> 19297803

KRAS mutations and epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19297803

Source DB:  PubMed          Journal:  Technol Eval Cent Assess Program Exec Summ


× No keyword cloud information.
  4 in total

1.  Practical ethics: establishing a pathway to benefit for complex pharmacogenomic tests.

Authors:  S B Haga; W Burke
Journal:  Clin Pharmacol Ther       Date:  2011-07       Impact factor: 6.875

2.  KRAS mutational analysis for colorectal cancer. Application: pharmacogenomic.

Authors:  Grace Wang; Robin K Kelley
Journal:  PLoS Curr       Date:  2010-09-02

3.  Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations.

Authors:  Chih-Chieh Chen; Tze-Kiong Er; Yen-Yi Liu; Jenn-Kang Hwang; Maria Jesus Barrio; Maximiliano Rodrigo; Enrique Garcia-Toro; Marta Herreros-Villanueva
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

Review 4.  Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update.

Authors:  David L Veenstra; Margaret Piper; James E Haddow; Stephen G Pauker; Roger Klein; Carolyn Sue Richards; Sean R Tunis; Benjamin Djulbegovic; Michael Marrone; Jennifer S Lin; Alfred O Berg; Ned Calonge
Journal:  Genet Med       Date:  2012-09-06       Impact factor: 8.822
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.